Literature DB >> 21498152

Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada.

Nisha Andany1, Janet M Raboud, Sharon Walmsley, Christina Diong, Sean B Rourke, Sergio Rueda, Anita Rachlis, Wendy Wobeser, Rodger D Macarthur, Louise Binder, Ron Rosenes, Mona R Loutfy.   

Abstract

PURPOSE: This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario.
METHODS: This was a cross-sectional analysis of the Ontario Cohort Study (OCS), a prospective study of HIV-positive patients in Ontario. Lipodystrophy was defined as at least 1 major or 2 minor self-reported changes of peripheral lipoatrophy and/or central lipohypertrophy. Prevalence, type, and severity were compared by ethnicity (Black, White, or Other) and gender. Univariate and multivariate logistic regression analyses identified predictors of lipodystrophy.
RESULTS: Data were available for 778 participants (659 men, 119 women). There were 517 Whites, 121 Blacks, and 140 patients of Other ethnicities. In univariate analyses, Whites reported more peripheral lipoatrophy (P = .004) and abdominal lipohypertrophy (P = .04); these ethnic differences were observed in males (P = .05 and P = .03, respectively) but not females. Males reported more peripheral lipoatrophy (P = .01), whereas females had more central lipohypertrophy (P < .0001) and mixed fat redistribution (P < .0001). Multivariable regression analyses revealed Black women to be most vulnerable to lipodystrophy (P = .02), particularly lipohypertrophy (P < .0001).
CONCLUSIONS: Ethnicity and gender are important factors influencing lipodystrophy. Combining lipoatrophy and lipohypertrophy into a single entity is not appropriate. Black women were most vulnerable to lipohypertrophy, which has important implications for antiretroviral therapy roll-out in Africa.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21498152     DOI: 10.1310/hct1202-89

Source DB:  PubMed          Journal:  HIV Clin Trials        ISSN: 1528-4336


  16 in total

Review 1.  Rare adipose disorders (RADs) masquerading as obesity.

Authors:  Karen L Herbst
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.

Authors:  N Agarwal; A Balasubramanyam
Journal:  Adipocyte       Date:  2014-10-30       Impact factor: 4.534

3.  A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Authors:  Jordan E Lake; Grace A McComsey; Todd M Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; M Sean Boger; Ralph R Turner; Heather E McCreath; Judith S Currier
Journal:  AIDS Patient Care STDS       Date:  2012-07-23       Impact factor: 5.078

4.  Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.

Authors:  Sabra L Klein
Journal:  Bioessays       Date:  2012-09-26       Impact factor: 4.345

Review 5.  Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?

Authors:  Jennifer Totonchy; Ethel Cesarman
Journal:  Curr Opin Virol       Date:  2016-09-23       Impact factor: 7.090

6.  Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy.

Authors:  Laura Young; David A Wohl; William B Hyslop; Yueh Z Lee; Sonia Napravnik; Aimee Wilkin
Journal:  HIV Clin Trials       Date:  2015-08-07

7.  Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.

Authors:  Kristina Thorsteinsson; Steen Ladelund; Søren Jensen-Fangel; Isik Somuncu Johansen; Terese L Katzenstein; Gitte Pedersen; Merete Storgaard; Niels Obel; Anne-Mette Lebech
Journal:  BMC Infect Dis       Date:  2012-11-12       Impact factor: 3.090

8.  Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study.

Authors:  Janet Raboud; DeSheng Su; Ann N Burchell; Sandra Gardner; Sharon Walmsley; Ahmed M Bayoumi; Sandra Blitz; Curtis Cooper; Irving Salit; Jeff Cohen; Sean B Rourke; Mona R Loutfy
Journal:  BMC Med Res Methodol       Date:  2013-03-05       Impact factor: 4.615

9.  Switch to Raltegravir From Protease Inhibitor or Nonnucleoside Reverse-Transcriptase Inhibitor Does not Reduce Visceral Fat In Human Immunodeficiency Virus-Infected Women With Central Adiposity.

Authors:  Jordan E Lake; Grace A McComsey; Todd Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; Judith S Currier
Journal:  Open Forum Infect Dis       Date:  2015-04-26       Impact factor: 3.835

10.  Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.

Authors:  Anne Langkilde; Janne Petersen; Jens Henrik Henriksen; Frank Krieger Jensen; Jan Gerstoft; Jesper Eugen-Olsen; Ove Andersen
Journal:  Immun Ageing       Date:  2015-08-04       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.